Crinetics pharmaceuticals, inc. (CRNX)
Balance Sheet / Yearly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Dec'17
Assets
Current assets:
Cash and cash equivalents

50,917

40,326

66,579

59,716

62,833

44,973

169,654

68,408

14,192

Investment securities

61,885

78,066

65,094

85,258

94,379

118,902

-

-

-

Prepaid expenses and other current assets

4,366

4,947

3,731

2,784

1,903

2,808

1,387

1,536

973

Total current assets

117,168

123,339

135,404

147,758

159,115

166,683

171,041

69,944

15,165

Property and equipment, net

3,771

3,946

4,035

4,264

4,465

4,232

4,353

1,808

400

Operating lease right-of-use asset

2,445

2,510

2,570

2,627

2,683

-

-

-

-

Restricted cash

500

500

500

500

500

500

500

500

-

Other assets

-

82

-

-

-

-

789

2,451

33

Total assets

123,884

130,377

142,509

155,149

166,763

171,415

176,683

74,703

15,598

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued expenses

8,296

5,498

2,113

2,705

2,003

5,265

1,398

2,603

403

Accrued compensation and related expenses

1,711

2,118

2,592

1,802

1,511

2,279

-

-

315

Other current liabilities

753

724

3,177

3,243

5,304

381

4,116

3,035

179

Total current liabilities

10,760

8,340

7,882

7,750

8,818

7,925

5,514

5,638

897

Operating lease liability, non-current

4,648

4,849

5,044

5,226

5,401

-

-

-

-

Unvested stock liability

39

49

60

72

150

202

209

217

3

Deferred rent

-

-

-

-

-

3,063

3,437

1,050

20

Total liabilities

15,447

13,238

12,986

13,048

14,369

11,190

9,160

6,905

920

Commitments and contingencies (Note 7)

-

-

-

-

-

-

0

0

-

Convertible preferred stock, $0.001 par; no shares authorized, issued and outstanding at December 31, 2018; 38,350,914 shares authorized, 28,763,179 shares issued and outstanding, liquidation preference of $30,000 at December 31, 2017

-

-

-

-

-

-

-

92,975

29,700

Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000 shares authorized; no shares issued or outstanding at March 31, 2020 or at December 31, 2019

-

-

-

-

-

-

0

-

-

Common stock and paid-in capital, $0.001 par value; 200,000 shares authorized; 24,614 and 24,587 shares issued and outstanding at March 31, 2020; 24,296 and 24,263 shares issued and outstanding at December 31, 2019

219,432

210,793

208,578

206,690

204,645

203,544

-

-

-

Common stock, $0.001 par; 200,000,000 shares authorized, 24,187,568 shares issued and 24,060,510 shares outstanding at December 31, 2018; 50,500,000 shares authorized, 2,076,171 shares issued and 1,549,575 shares outstanding at December 31, 2017

-

-

-

-

-

-

24

2

1

Additional paid-in capital

-

-

-

-

-

-

202,384

2,118

1,242

Accumulated other comprehensive income

167

148

198

234

145

61

-

-

-

Accumulated deficit

-111,162

-93,802

-79,253

-64,823

-52,396

-43,380

-34,885

-27,297

-16,265

Total stockholders’ equity

108,437

117,139

129,523

142,101

152,394

160,225

167,523

-25,177

-15,022

Total liabilities and stockholders’ equity

123,884

130,377

142,509

155,149

166,763

171,415

176,683

74,703

15,598